Eli Lilly and Company (LLY)
Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)
Eli Lilly stock has recovered resoundingly, outperforming the S&P 500, Novo Nordisk, and healthcare peers after a period of decline. LLY's robust pipeline, expansion into cardiometabolic and oncology adjacencies, and manufacturing readiness support its competitive edge over NVO. Despite near-term gross margin pressures, LLY's valuation is de-risked, and its growth strategy could bolster near-term catalysts from its diversified pipeline.
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.
Eli Lilly (LLY) Laps the Stock Market: Here's Why
Eli Lilly (LLY) closed the most recent trading day at $839.87, moving +2.44% from the previous trading session.
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thursday.
Another Surging Pharma Stock to Watch Right Now
Pharmaceutical concern Eli Lilly And Co (NYSE:LLY ) is charging 7.2% higher to trade at $821.20 this afternoon.
Drug-Pricing Deals And Discounted Bets: Why LLY Stock Is A Core Pick In Our Top 10
Eli Lilly stock (NYSE: LLY) surged 5% yesterday, initially driven by news of a Pfizer deal with the White House to lower drug prices in exchange for tariff immunity. Following this, reports surfaced that the broader pharmaceutical companies are in active discussions with the administration regarding discounted drugs.
Eli Lilly in negotiations with Trump administration for the next pharma deal
CNBC's Eamon Javers reports on news regarding the White House.
Is Lilly (LLY) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Eli Lilly and Company (NYSE:LLY ) Bernstein 2nd Annual Global Healthcare Conference September 25, 2025 8:00 AM EDT Company Participants Lucas Montarce - Executive VP & CFO Mike Czapar - Director of Investor Relations Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
Eli Lilly's boss calls UK the 'worst' European country for drug prices
Eli Lilly Chief Executive Dave Ricks said Britain was "probably the worst country in Europe" for drug prices in an interview with the Financial Times, intensifying pressure on the government to improve market conditions for drugmakers.
Eli Lilly to Build $6.5 Billion Ingredient-Manufacturing Facility in Texas
The planned site, which will be used to manufacture the company's first oral weight-loss drug, is expected to be operational within five years.
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
